Korean biotech that licenses a hyaluronidase enzyme technology converting IV biologic drugs into subcutaneous injections.
Korean biotech that licenses a hyaluronidase enzyme technology converting IV biologic drugs into subcutaneous injections.
Earns by licensing its enzyme to drug companies for upfront payments when a deal is signed, milestone payments as development proceeds, and royalties once the injectable form is sold, so income is lumpy and depends on partners' launches. Merck's subcutaneous Keytruda, approved in 2025, is the most prominent product using it.
In one line: Korea's Halozyme — the rival subcutaneous drug-delivery enzyme maker..
Moat: narrow (IP/patents, switching costs). Patented enzyme technology is now embedded in approved drugs like Keytruda Qlex, though it faces Halozyme patent litigation.
Headquarters: Daejeon, South Korea · Founded: 2008 · Employees: 161
Size ALTEOGEN (196170.KS) is a South Korea Health Care company (Biotechnology) with a market value of $8.80B, the 51st largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩170,900 on 18 Nov 2026.
Performance Over six months the shares fell 55.6%, against +24.1% for the median peer and -37.2% for the South Korea market (cap-weighted) — lowest of 21 in its peer set.
Growth Revenue grew 60.6% over the last twelve months (peer median +25.2%); the operating margin is 53.0% (peer median 8.5%).
Valuation It trades at 42.0× forward earnings against a peer median of 35.0× (4th most expensive of 11).
Price implies For today's price to make sense, revenue must grow about 25% a year for seven years (Req g). Recent delivered growth is +38%, so the hurdle is -14 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 45.3 points above its cost of capital (7.0% WACC).
Next results Next results expected around 22 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩325B | ₩216B | ₩103B | ₩96.5B | ₩28.8B |
| Revenue growth | — | +110% | +7% | +235% | — |
| Gross profit | ₩299B | ₩176B | ₩81.4B | ₩82.2B | ₩9.41B |
| EBITDA | ₩183B | ₩112B | ₩28.3B | -₩6.40B | -₩26.7B |
| Net income | ₩212B | ₩142B | ₩62.3B | -₩3.37B | -₩8.15B |
| Free cash flow | ₩116B | ₩101B | ₩50.3B | -₩8.98B | -₩24.2B |
| Capital expenditure | ₩38.0B | ₩33.4B | ₩24.5B | ₩43.5B | ₩42.5B |
| Total debt | ₩108B | ₩101B | ₩102B | ₩83.8B | ₩85.5B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| ALTEOGEN 196170.KS | $8.80B | -56% | +61% | 53% | 42.0× | 24.6% |
| Halozyme Therapeutics HALO | $10.9B | +39% | +45% | 57% | 9.5× | -0.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 196170.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -26.0% | -5.4% | 4th lowest of 21 |
| 6-month return | -55.6% | +24.1% | lowest of 21 |
| Distance from 52-week high | -70.0% | -26.2% | lowest of 21 |
| Revenue growth (TTM) | +60.6% | +25.2% | 4th highest of 16 |
| Operating margin | 53.0% | 8.5% | 2nd highest of 17 |
| Forward P/E | 42.0× | 35.0× | 4th most expensive of 11 |
| Growth the price implies (Req g, 7 yrs) | 24.6% | 15.7% | 5th most demanding of 11 |
| Growth delivered (Del g) | +38.5% | +14.3% | 3rd highest of 11 |
| Hurdle (Req g minus delivered) | -13.9 pp | +0.0 pp | 3rd least demanding of 11 |
| ROIC minus cost of capital | +45.3 pp | -1.5 pp | highest of 14 |
| EV / EBITDA | 62.2× | 23.7× | most expensive of 9 |
| Net debt / EBITDA | -1.8× | -1.0× | 5th least indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| ALTEOGEN 196170.KS | South Korea | $8.80B | -56% | +61% | 53% | 42.0× | 24.6% | +38.5% |
| Genscript Biotech 1548.HK | Hong Kong | $8.69B | +133% | +53% | 12% | 294.1× | 36.9% | +19.8% |
| Summit Therapeutics SMMT | United States | $8.40B | -41% | n/a | n/a | n/a | n/a | n/a |
| Vaxcyte PCVX | United States | $9.26B | +24% | n/a | n/a | n/a | n/a | n/a |
| Krystal Biotech KRYS | United States | $9.34B | +4% | +26% | 48% | 36.3× | 13.1% | +26.0% |
| Twist Bioscience TWST | United States | $7.93B | +117% | +22% | -29% | n/a | n/a | n/a |
| Sichuan Kelun Pharmaceutical 002422.SZ | China | $10.1B | +35% | 0% | 9% | 35.6× | 6.2% | +2.3% |
| 10x Genomics TXG | United States | $7.51B | +138% | -4% | -11% | n/a | 47.2% | +16.6% |
| Kymera Therapeutics KYMR | United States | $10.3B | +50% | +134% | -396% | n/a | n/a | n/a |
| CG Oncology CGON | United States | $7.15B | +24% | +184% | -4,294% | n/a | n/a | n/a |
| Halozyme Therapeutics HALO | United States | $10.9B | +39% | +45% | 57% | 9.5× | -0.3% | +39.2% |
| Axsome Therapeutics AXSM | United States | $7.05B | -42% | +54% | -19% | 77.1× | n/a | n/a |
| Immunovant IMVT | United States | $6.86B | -7% | n/a | n/a | n/a | n/a | n/a |
| Bio-Techne TECH | United States | $11.4B | +56% | +1% | 21% | 34.4× | 31.6% | +5.5% |
| BioMarin Pharmaceutical BMRN | United States | $11.9B | +22% | +20% | 19% | 11.2× | 8.2% | +12.0% |
| Cspc Pharma 1093.HK | Hong Kong | $12.0B | +10% | +25% | 28% | 9.1× | -10.7% | +0.1% |
| Kodiak Sciences KOD | United States | $6.40B | +170% | n/a | n/a | n/a | n/a | n/a |
| Arrowhead Pharmaceuticals ARWR | United States | $6.09B | -44% | -46% | -157% | n/a | n/a | n/a |
| Scholar Rock SRRK | United States | $5.86B | -1% | n/a | -71,732% | n/a | n/a | n/a |
| Elanco Animal Health ELAN | United States | $13.3B | +28% | +12% | 8% | 21.5× | 32.9% | +7.6% |
| Caris Life Sciences CAI | United States | $5.59B | +24% | +61% | 13% | 79.4× | 18.2% | +61.5% |